Akynzeo Capsule is a combination medication that contains two active ingredients: Netupitant (300 mg) and Palonosetron (0.5 mg). This formulation is specifically designed to prevent nausea and vomiting associated with chemotherapy, making it a vital option for patients undergoing cancer treatment. Netupitant is a neurokinin-1 (NK1) receptor antagonist that works by blocking the action of substance P, a neuropeptide involved in the vomiting reflex. Palonosetron, on the other hand, is a selective serotonin 5-HT3 receptor antagonist that helps to inhibit the signals that trigger nausea and vomiting. Together, these components provide a synergistic effect, enhancing the overall efficacy of the treatment. Akynzeo is typically administered as a single oral dose, making it convenient for patients who may already be dealing with the challenges of cancer therapy. This medication not only improves the quality of life for patients by reducing the side effects of chemotherapy but also allows for better adherence to treatment regimens.